Coherus BioSciences Inc (CHRS)

Currency in USD
1.175
+0.035(+3.07%)
Closed·
1.160-0.020(-1.69%)
·
CHRS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CHRS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.1301.209
52 wk Range
0.6602.430
Key Statistics
Prev. Close
1.14
Open
1.14
Day's Range
1.13-1.209
52 wk Range
0.66-2.43
Volume
862.59K
Average Volume (3m)
1.35M
1-Year Change
-22.07%
Book Value / Share
1.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CHRS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.700
Upside
+300.00%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Coherus BioSciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Coherus BioSciences Inc Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Employees
177

Coherus BioSciences Inc SWOT Analysis


Oncology Pivot
Coherus BioSciences transitions from biosimilars to immuno-oncology, facing challenges and opportunities in its strategic transformation
Casdozo's Promise
Explore the potential of casdozo, Coherus's anti-IL-27 antibody, showing encouraging results in liver cancer treatment and driving pipeline advancement
Financial Tightrope
Delve into Coherus's complex financial landscape, balancing debt obligations and cash burn against the need to fund ongoing research and development
Market Dynamics
Analysts set price targets ranging from $1.50 to $7.00, reflecting varied perspectives on Coherus's ability to navigate competitive pressures and pipeline potential
Read full SWOT analysis

Coherus BioSciences Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of -$0.34 missed forecast by 30.77%, stock fell 3.49% after hours despite slight revenue beat
  • Revenue up 36% QoQ and 65% YoY to $10.25M, driven by PD-1 inhibitor Loktorzi; $238M cash provides runway through 2026
  • Projecting $40-$50M Loktorzi revenue in 2025, peak by 2028; exploring ex-US licensing and combination therapies
  • Cost savings expected from headcount reductions; SG&A forecast at $90-$100M for 2025
  • Analyst price targets range $1.10-$7.00; company labeled 'GOOD' financial health despite YTD stock decline of 35.95%
Last Updated: 08/08/2025, 12:20
Read Full Transcript

Compare CHRS to Peers and Sector

Metrics to compare
CHRS
Peers
Sector
Relationship
P/E Ratio
2.3x−2.2x−0.6x
PEG Ratio
0.00−0.010.00
Price/Book
1.1x0.9x2.6x
Price / LTM Sales
0.5x1.2x3.3x
Upside (Analyst Target)
-161.0%38.7%
Fair Value Upside
Unlock33.6%5.1%Unlock

Analyst Ratings

3 Buy
3 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.700
(+300.00% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.34 / -0.26
Revenue / Forecast
10.25M / 10.16M
EPS Revisions
Last 90 days

CHRS Income Statement

People Also Watch

27.580
VKTX
+3.61%
0.490
PSTV
-1.03%
48.950
ASTS
+1.45%
18.34
SRPT
+1.49%

FAQ

What Stock Exchange Does Coherus BioSciences Trade On?

Coherus BioSciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Coherus BioSciences?

The stock symbol for Coherus BioSciences is "CHRS."

What Is the Coherus BioSciences Market Cap?

As of today, Coherus BioSciences market cap is 136.57M.

What Is Coherus BioSciences's Earnings Per Share (TTM)?

The Coherus BioSciences EPS (TTM) is 0.51.

When Is the Next Coherus BioSciences Earnings Date?

Coherus BioSciences will release its next earnings report on 09 Nov 2025.

From a Technical Analysis Perspective, Is CHRS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Coherus BioSciences Stock Split?

Coherus BioSciences has split 0 times.

How Many Employees Does Coherus BioSciences Have?

Coherus BioSciences has 177 employees.

What is the current trading status of Coherus BioSciences (CHRS)?

As of 28 Aug 2025, Coherus BioSciences (CHRS) is trading at a price of 1.175, with a previous close of 1.14. The stock has fluctuated within a day range of 1.130 to 1.209, while its 52-week range spans from 0.660 to 2.430.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.